Q95LA0
Gene name |
FATE1 (FATE) |
Protein name |
Fetal and adult testis-expressed transcript protein homolog |
Names |
|
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:281153 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q95LA0
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q95LA0-F1 | Predicted | AlphaFoldDB |
32 variants for Q95LA0
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs443543350 | 17 | K>N | No | EVA | |
| rs451969683 | 20 | D>A | No | EVA | |
| rs440833497 | 25 | S>T | No | EVA | |
| rs478968637 | 29 | N>K | No | EVA | |
| rs443023486 | 31 | E>Q | No | EVA | |
| rs459731159 | 55 | V>G | No | EVA | |
| rs132805192 | 60 | V>G | No | EVA | |
| rs473961577 | 83 | V>G | No | EVA | |
| rs719197908 | 83 | V>I | No | EVA | |
| rs444228688 | 86 | V>M | No | EVA | |
| rs462789182 | 88 | E>G | No | EVA | |
| rs471689416 | 91 | D>G | No | EVA | |
| rs438754115 | 92 | G>A | No | EVA | |
| rs137065713 | 95 | Q>P | No | EVA | |
| rs448857596 | 101 | G>R | No | EVA | |
| rs482825826 | 103 | S>F | No | EVA | |
| rs469458164 | 104 | Q>H | No | EVA | |
| rs450980301 | 104 | Q>P | No | EVA | |
| rs433444899 | 106 | M>T | No | EVA | |
| rs445514905 | 107 | R>T | No | EVA | |
| rs466884147 | 108 | S>A | No | EVA | |
| rs433994503 | 110 | F>V | No | EVA | |
| rs455721386 | 111 | E>G | No | EVA | |
| rs439922249 | 112 | R>C | No | EVA | |
| rs460744241 | 114 | E>G | No | EVA | |
| rs443064372 | 131 | M>I | No | EVA | |
| rs461631943 | 132 | E>K | No | EVA | |
| rs482980682 | 132 | E>V | No | EVA | |
| rs450088032 | 133 | I>V | No | EVA | |
| rs458958107 | 136 | R>G | No | EVA | |
| rs453589856 | 140 | M>L | No | EVA | |
| rs474980334 | 160 | V>G | No | EVA |
No associated diseases with Q95LA0
No regional properties for Q95LA0
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| No domain, repeats, and functional sites for Q95LA0 | |||
Functions
5 GO annotations of cellular component
| Name | Definition |
|---|---|
| endoplasmic reticulum | The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached). |
| endoplasmic reticulum membrane | The lipid bilayer surrounding the endoplasmic reticulum. |
| integral component of membrane | The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| mitochondria-associated endoplasmic reticulum membrane | A zone of apposition between endoplasmic-reticulum and mitochondrial membranes, structured by bridging complexes. These contact sites are thought to facilitate inter-organelle calcium and phospholipid exchange. |
| mitochondrial outer membrane | The outer, i.e. cytoplasm-facing, lipid bilayer of the mitochondrial envelope. |
1 GO annotations of molecular function
| Name | Definition |
|---|---|
| ubiquitin protein ligase binding | Binding to a ubiquitin protein ligase enzyme, any of the E3 proteins. |
3 GO annotations of biological process
| Name | Definition |
|---|---|
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| negative regulation of apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
| negative regulation of mitochondrial calcium ion concentration | Any process that decreases the concentration of calcium ions in mitochondria. |
No homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| No homologous proteins | ||||
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAGGAVPNLK | EKMQVPKDED | LLLGSFRDNQ | ECSVAAEMKE | HMSRLLGASQ | RRQRVDPKAV |
| 70 | 80 | 90 | 100 | 110 | 120 |
| GSAVVWNTAA | NQSKKMGPQL | RGVGVVGEQG | DGGAQPQENP | GGSQGMRSQF | ERRELNTLAE |
| 130 | 140 | 150 | 160 | 170 | |
| IGLEELNELE | MEIMRRQLFM | ITERLRYLED | QSATWHQREV | LLFTMLLSSC | ITNLWLWMRQ |